# AI in Drug Discovery

## You (2025-03-23T19:32:56.625000+00:00)

You are an investigative Harvard Business School Professor synthesizing scholarly research, whitepapers, and strategic articles into analytically rigorous, decision-relevant insights for Fortune 500 executives and senior leaders. Your goal is to uncover nuanced insights into executive decision-making, strategic reasoning, cognitive biases, and influential factors.

Your insights must explicitly:

- Highlight executive thought processes, strategic reasoning, and factors influencing decisions.
- Critically examine implicit biases, cognitive models, flawed assumptions, and reasoning gaps.
- Clearly separate empirical evidence from speculation, marking uncertainty explicitly when evidence is insufficient.

---

## Required Output Format

Always begin your analysis with:

## **Title of Paper**

**Abstract:**

Briefly address:

- **Key Themes:** Identify central themes.
- **Core Motivations:** Outline organizational or theoretical challenges driving the research.
- **Methodological Clarification:** Summarize methods clearly noting implications for reliability.
- **Relevance Assessment:** Connect findings explicitly to contemporary executive concerns.

## Grounded Executive Insights

For each significantÂ discussion topic, theme, or strategic dilemma presented in the research paper, clearly present your insights structured into three distinct sections:

---

**1. Insight Statement**

Craft concise, critical statements explicitly challenging common assumptions or integrating surprising findings. Ensure insights question prevailing narratives, logic, or conclusions to foster executive reflection.

**Immediately after each Insight Statement, include one of the following tags:**

- **[Empirical]** â€” Directly supported by specific data or stated findings in the paper.
- **[Inferred]** â€” Reasonable extension based on the paperâ€™s themes or methodology, but not explicitly stated.
- **[Speculative]** â€” Analytically plausible, but not supported by the paper and introduced to prompt deeper reflection.

If the paper lacks sufficient content for an insight, clearly state:

**â€œNo relevant data or insight on [topic] was found in this paper.â€**

**Examples:**

- "While most experts conclude that taking short breaks is vital to stay productive, study participants consistently viewed short breaks as unimportant and avoidable." **[Empirical]**
- "Although networking was frequently cited as a conference benefit, the relaxed event tone suggests that meaningful connections require more deliberate strategies." **[Inferred]**
- "Despite no direct evidence, the authors' framing implies leaders may be overconfident in scenario planning outcomes." **[Speculative]**

**2. Executive Decision-Making Context**

For each subsection below, briefly outline the strategic dynamics and tag the overall section with one of:

- **[Empirical]** â€” Directly supported by data or explicit statements in the paper.
- **[Inferred]** â€” Reasonable interpretation of author framing, themes, or outcomes.
- **[Speculative]** â€” Logically plausible but not supported by the paper.

If not applicable or not present in the paper, state:

**â€œThis section is omitted due to lack of supporting content in the paper.â€**

**Strategic Dilemma:**

...

**Underlying Beliefs & Biases:**

...

**Expected vs. Actual Outcomes:**

...

**Broader Implications:**

...

**[Inferred]**

**3. Supporting Context**

Ground your insights explicitly in empirical evidence, highlighting methods, key findings, and limitations. Convert complex statistics into clear percentages or ratios where possible, transparently noting approximations. Explicitly differentiate between empirical support and speculative assertions.

**At the end of this section, include one of the following tags:**

- **[Empirical]**
- **[Inferred]**
- **[Speculative]**

If no empirical data is available, state:

**â€œNo empirical data available to support this insight in the paper.â€**

**Example:**

"This analysis used customer engagement data from five U.S. banks (2019â€“2023), analyzing 2 million profiles via regression models controlling for demographics. Hybrid customers showed 18% lower churn and opened 1.8x more secondary accounts than digital-only users, indicating higher lifetime value. Limitations include external economic factors and evolving generational preferences." **[Empirical]**

---

## Source Relevance Audit

After completing the full analysis, include the following diagnostic to reflect on the fit and integrity of the source material:

### **Source Relevance Audit**

- **Coverage Fit:** [High | Moderate | Low] â€” Does the paper sufficiently address executive decision-making or strategic reasoning?
- **Bias & Cognitive Modeling Content:** [Present | Absent | Implied Only]
- **Clarity of Methods & Outcomes:** [Clear | Ambiguous | Unavailable]
- **Areas with No Data:** Clearly list any of the following sections that lacked support in the paper:
    - Insight Statement
    - Executive Decision-Making Context
    - Supporting Context

This audit helps determine whether the paper warrants further analysis or should be deprioritized.

---

## Internal Behaviour Guide for you (Do not include in output)

### **Analytical Approach**

Implicitly utilize these analytical frameworks without explicitly enumerating them in your output:

- **Inductive Thematic Analysis** â€“ Let themes emerge without imposing external framing
- **Latent Thematic Analysis** â€“ Seek implicit motivations or hidden decision structures
- **Reflexive Analysis** â€“ Reflect on your own analytical assumptions and flag overreach

### **Traceability-First Reasoning**

Do not fabricate or extrapolate content to fulfill structural expectations. Where the paper lacks material:

- Leave the section blank,
- Tag speculative reasoning explicitly, and
- Include a clear note in the final Source Relevance Audit.

---

Maintain this structure to ensure clarity, traceability, and analytical integrity for executive decision-makers.

## ChatGPT (2025-03-23T19:32:58.708594+00:00)

## **The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies**

**Abstract:**

- **Key Themes:** This paper reviews how artificial intelligence (AI) is reshaping drug discovery through advanced machine learning and deep learning techniques, with particular attention to predictive efficacy, toxicity assessments, and the design of novel compounds.
- **Core Motivations:** It addresses the imperative to accelerate the traditionally slow and costly drug development process, overcome limitations of hitâ€andâ€miss experimental methods, and mitigate risks arising from data quality and ethical concerns.
- **Methodological Clarification:** The review synthesizes empirical case studies, literature analyses, and expert opinions (including an experiment using ChatGPT for scientific writing) to illustrate AIâ€™s capabilities and limitations. The iterative revision process by human experts further refines AI-generated content, underscoring the balance between algorithmic output and domain expertise.
- **Relevance Assessment:** For contemporary executives, the findings underscore both the strategic promise of AI in reducing development timelines and costs, and the imperative to manage risks related to data bias, ethical issues, and overreliance on automated systems.

---

### **Grounded Executive Insights**

---

**1. Insight Statement**

"AI integration in drug discovery transforms traditional R&D by significantly accelerating candidate identification and reducing costs, yet it mandates rigorous oversight to mitigate challenges related to data quality and interpretability." **[Empirical]**

**2. Executive Decision-Making Context**

- **Strategic Dilemma:** Executives must decide whether to invest in cutting-edge AI capabilities versus maintaining traditional experimental methods, weighing rapid innovation against the risks of unreliable data.
- **Underlying Beliefs & Biases:** There is a potential bias toward overvaluing technological solutions and underestimating the complexities of data integrity and algorithmic limitations.
- **Expected vs. Actual Outcomes:** While AI promises efficiency gains and cost savings, actual implementation may reveal unforeseen challenges in data heterogeneity and interpretability that require continuous human validation.
- **Broader Implications:** The shift necessitates investment in robust data infrastructure and a cultural pivot toward hybrid decision-making that integrates both algorithmic insights and expert judgment.
**[Empirical]**

**3. Supporting Context**

The paper presents multiple empirical examplesâ€”such as ML models predicting drug efficacy and toxicity with improved accuracyâ€”and outlines strategies like data augmentation and explainable AI. These concrete instances demonstrate how AI-driven methods can streamline the discovery process while also flagging inherent limitations that must be managed through diligent oversight.
**[Empirical]**

---

**1. Insight Statement**

"Successful AI adoption in drug discovery depends critically on bridging the gap between technical experts and pharmaceutical scientists, thereby challenging siloed decision-making practices and fostering cross-disciplinary collaboration." **[Empirical]**

**2. Executive Decision-Making Context**

- **Strategic Dilemma:** Leaders face the challenge of integrating diverse expertise to harness AIâ€™s full potential while ensuring that domain-specific insights are not lost in the technology-centric approach.
- **Underlying Beliefs & Biases:** There is a risk of undervaluing the role of human expertise, with an overreliance on technical teams potentially leading to misaligned priorities.
- **Expected vs. Actual Outcomes:** While collaborative frameworks are expected to yield innovative drug candidates, traditional departmental silos may impede this synergy unless deliberately restructured.
- **Broader Implications:** Embracing cross-functional teams could lead to more agile decision-making and foster a culture that values both technological prowess and scientific rigor.
**[Inferred]**

**3. Supporting Context**

The review details examples of industry collaborationsâ€”such as partnerships between established pharmaceutical companies and AI firmsâ€”that illustrate how merging AI capabilities with deep domain knowledge can enhance drug discovery. These case studies provide tangible evidence of improved clinical trial designs and accelerated compound validation through integrated expertise.
**[Empirical]**

---

**1. Insight Statement**

"While AI promises transformative efficiency in drug discovery, overreliance on algorithmic outputs without sufficient human oversight may lead to strategic missteps, emphasizing the necessity for balanced decision-making." **[Empirical]**

**2. Executive Decision-Making Context**

- **Strategic Dilemma:** Decision-makers must balance the lure of rapid, automated insights against the critical need for human judgment to interpret and validate AI-generated predictions.
- **Underlying Beliefs & Biases:** There is an inherent cognitive bias toward assuming that more data and automation invariably lead to better outcomes, which can downplay the value of expert review.
- **Expected vs. Actual Outcomes:** Overtrust in AI can result in the adoption of flawed drug candidates or misinterpreted safety profiles, whereas incorporating expert review tends to yield more reliable, actionable insights.
- **Broader Implications:** Institutions should institute rigorous review processes to ensure AI tools serve as supportive aids rather than definitive decision-makers, thereby safeguarding against potential errors.
**[Empirical]**

**3. Supporting Context**

Expert opinions within the paper criticize the use of AI tools (e.g., ChatGPT) for autonomous scientific writing, highlighting that AI-generated content requires substantial human intervention to correct inaccuracies. This critique serves as a cautionary tale for executives about the perils of unmoderated reliance on AI in critical decision processes.
**[Empirical]**

---

**1. Insight Statement**

"Ethical challengesâ€”including data bias and privacy concernsâ€”in AI-driven drug discovery represent strategic risks that, if unaddressed, can compromise both operational outcomes and corporate reputation." **[Empirical]**

**2. Executive Decision-Making Context**

- **Strategic Dilemma:** Leaders must balance the drive for innovation with the ethical responsibility to ensure data fairness and protect sensitive information, a trade-off that impacts both regulatory compliance and public trust.
- **Underlying Beliefs & Biases:** There is a tendency to prioritize speed and innovation over thorough ethical scrutiny, potentially overlooking long-term risks associated with biased data or privacy breaches.
- **Expected vs. Actual Outcomes:** Although AI adoption can enhance efficiency, insufficient attention to ethical governance may result in adverse regulatory, reputational, or even legal outcomes.
- **Broader Implications:** Establishing comprehensive ethical frameworks and robust data governance protocols is imperative for sustainable innovation and stakeholder confidence.
**[Empirical]**

**3. Supporting Context**

The paper explicitly discusses ethical considerations, emphasizing the need for data augmentation, explainable AI, and stringent oversight to counterbalance inherent biases. These discussions underscore that ethical vigilance is not just a regulatory requirement but a strategic imperative for long-term success in drug development.
**[Empirical]**

---

### **Source Relevance Audit**

- **Coverage Fit:** Moderate â€” While the paper provides robust insights into AIâ€™s impact on drug discovery and discusses related challenges and strategies, it does not focus primarily on executive decision-making processes.
- **Bias & Cognitive Modeling Content:** Implied Only â€” The discussion hints at cognitive biases (e.g., overreliance on automated outputs) and challenges inherent in decision-making, but it does not deeply analyze the cognitive models of executive behavior.
- **Clarity of Methods & Outcomes:** Clear â€” The paper outlines its methodological approach and presents empirical examples and case studies in a transparent manner, despite some reliance on AI-generated content requiring human revision.
- **Areas with No Data:**
  - **Executive Decision-Making Context:** The paper infers strategic implications for executives, yet it lacks direct empirical evidence focused specifically on executive thought processes and decision-making dynamics.

## You (2025-03-23T19:34:19.027000+00:00)

You are a critical Harvard Business School professor specializing in executive cognition and strategic behavior. Your role is to challenge surface-level insights by stress-testing themâ€”identifying hidden assumptions, contextual weaknesses, and scenarios where they fail. Do not suggest corrections, rewrite the insight, or recommend strategic actions. You are a devilâ€™s advocate, not an advisor.

The insight modules you are about to analyze come from the **previous message in this conversation**. Do not ask the user for input â€” instead, immediately begin parsing and evaluating the modules based on what was already provided.

---

### ğŸ“¥ INPUT INSTRUCTIONS:

You will receive a **series of one or more Insight Modules**. Each module begins with an `Insight Statement:` line.

A new module starts wherever another `Insight Statement:` appears.

Each module may contain:

- `Insight Statement:` (1â€“2 sentence claim) â† always the start of a new module
- `Executive Decision-Making Context:` â€“ This section may appear:
    - As structured subcomponents (e.g., Strategic Dilemma, Biases, etc.)
    - As a single narrative paragraph
    - Or may be **absent altogether**
- `Supporting Context:` (evidence, rationale, or background)

Your task is to:

1. **Scan for every `Insight Statement:`** to identify where each module begins.
2. Treat the content between one `Insight Statement:` and the next as one complete insight module.
3. Evaluate **each module independently** using the full structure below.

If any expected components are:

- **Blended into a narrative**, extract what you can based on conceptual cues.
- **Missing**, proceed using what's available (especially the Insight Statement and Supporting Context).

---

### ğŸ¯ OBJECTIVE:

For **each** Insight Module, perform a critical stress test. Your analysis must:

1. Determine whether the insight is **context-dependent or overly generalized**.
2. Identify any **implicit assumptions or flawed mental models**.
3. Construct a **plausible, well-defined scenario** where the insight would **not** hold true.
4. Optionally reflect on any **ambiguity, trade-offs, or conceptual tensions**.

Repeat the output format **for each module**, in the order they appear.

---

### ğŸ“¤ OUTPUT FORMAT (Repeat per module):

**INSIGHT MODULE #:** [e.g., Insight Module 1]

ORIGINAL INSIGHT:

[Copy the original Insight Statement exactly as written.]

ğŸ”¹ COUNTERFACTUAL SCENARIO:

Describe a clearly defined fictional situation where this insight breaks down. Include:

- Organization type or industry
- Decision environment (constraints, pressures)
- Outcome divergence

ğŸ”¹ ASSUMPTIONS & BIASES:

List hidden assumptions or cognitive biases embedded in the insight. Examples:

- Overconfidence
- Simplistic causality
- Trend-following
- Groupthink
- Status quo bias
- Overreliance on outcome-based reasoning

ğŸ”¹ CONTEXT LIMITATIONS:

Where does this insight potentially break down? Consider geography, industry, company maturity, regulatory environments, etc.

ğŸ”¹ FINAL CRITIQUE:

In 1â€“2 sentences, surface any conceptual ambiguity, competing logics, or trade-offs. Examples:

- Tension between stability and innovation
- Internal contradictions in the rationale
- Situations where alternate interpretations would be valid

*Do not suggest improvements or actions.*

---

### âš™ï¸ CONFIGURABLE PARAMETERS:

Optional metadata you may include:

- `"include_reflection": true/false` â€“ Toggles whether to add a Reflection section per module.

Do **not** assume a fixed number of modules. Automatically identify all modules by scanning for repeated `Insight Statement:` markers, and analyze them in sequence.

---

### ğŸ›¡ï¸ BOUNDARY CONDITIONS:

- Do **not** rewrite or reframe the insight.
- Do **not** offer executive advice.
- Do **not** cite real-world companies unless mentioned in the input.
- Maintain a tone of **skeptical professionalism**, not editorial opinion.
- If clarity is lacking, note ambiguity but proceed.

---

### ğŸ¤– SELF-CHECK (Internal Behavior Guide):

For each module, ask yourself:

- Did I clearly show where and why the insight might fail?
- Did I stay grounded in business logic without editorializing?
- Did I complete **every** insight module, not just the first?
- Is my tone analytical, focused, and appropriately skeptical?

## ChatGPT (2025-03-23T19:34:20.406150+00:00)

**INSIGHT MODULE 1:**

ORIGINAL INSIGHT:

"AI integration in drug discovery transforms traditional R&D by significantly accelerating candidate identification and reducing costs, yet it mandates rigorous oversight to mitigate challenges related to data quality and interpretability." **[Empirical]**

ğŸ”¹ COUNTERFACTUAL SCENARIO:

In a boutique biotechnology startup focusing on highly specialized orphan drugs, integration of AI systems (due to limited historical data) significantly slows down candidate identification because models struggle with sparse datasets, resulting in increased overall costs and development delays.

ğŸ”¹ ASSUMPTIONS & BIASES:

- Simplistic causality: Assumes AI inherently leads to efficiency gains without consideration of initial conditions or data availability.
- Overconfidence: Implicitly expects algorithms to deliver uniformly reliable predictions regardless of domain specificity.
- Trend-following: Embeds a presumption that industry-wide trends towards AI will produce uniform outcomes.

ğŸ”¹ CONTEXT LIMITATIONS:

The insight falters in contexts marked by small datasets, highly novel therapeutic areas, or heavily regulated environments where AI's predictive capabilities become unreliable. Mature pharmaceutical firms with extensive, structured historical data differ vastly from innovative startups or niche markets.

ğŸ”¹ FINAL CRITIQUE:

This insight creates ambiguity by advocating rigorous oversight without defining its parameters clearly, thus setting up a tension between accelerating innovation and maintaining caution due to interpretative challenges.

---

**INSIGHT MODULE 2:**

ORIGINAL INSIGHT:

"Successful AI adoption in drug discovery depends critically on bridging the gap between technical experts and pharmaceutical scientists, thereby challenging siloed decision-making practices and fostering cross-disciplinary collaboration." **[Empirical]**

ğŸ”¹ COUNTERFACTUAL SCENARIO:

A highly compartmentalized pharmaceutical conglomerate demonstrates repeated successful AI-based compound discoveries precisely because clear boundaries allow focused domain expertise, minimized communication overhead, and faster technical validation cycles, contradicting the need for cross-disciplinary bridging.

ğŸ”¹ ASSUMPTIONS & BIASES:

- Groupthink: Assumes cross-disciplinary collaboration is universally beneficial without acknowledging potential inefficiencies from conflicting domain logics or knowledge asymmetry.
- Status quo bias: Implicitly assumes that silos are inherently negative, disregarding scenarios where clear boundaries expedite specialized productivity.

ğŸ”¹ CONTEXT LIMITATIONS:

This insight does not universally apply to organizations with effective, silo-based internal markets or highly specialized R&D operations that benefit from deliberate compartmentalization. It also fails in scenarios with extremely tight project timelines or competitive pressures demanding rapid domain-specific advancements.

ğŸ”¹ FINAL CRITIQUE:

The insight overlooks the complexity of cross-disciplinary interaction, implying a simplistic solutionâ€”bridge-buildingâ€”to complex organizational dynamics, and creates conceptual tension by ignoring the efficiencies generated by specialization and focus.

---

**INSIGHT MODULE 3:**

ORIGINAL INSIGHT:

"While AI promises transformative efficiency in drug discovery, overreliance on algorithmic outputs without sufficient human oversight may lead to strategic missteps, emphasizing the necessity for balanced decision-making." **[Empirical]**

ğŸ”¹ COUNTERFACTUAL SCENARIO:

A mid-sized generics pharmaceutical manufacturer fully automates its pipeline decisions through robust AI-driven validation models due to highly standardized drug formulations and regulatory clarity, successfully eliminating human oversight entirely and achieving superior efficiency and accuracy.

ğŸ”¹ ASSUMPTIONS & BIASES:

- Overreliance on outcome-based reasoning: Presumes that human oversight intrinsically improves strategic decisions without recognizing potential human biases and inefficiencies.
- Status quo bias: Suggests human involvement is always beneficial, implicitly discounting potential scenarios of human error or bias-induced inefficiencies.

ğŸ”¹ CONTEXT LIMITATIONS:

The assumption fails notably in mature, regulated markets or industries characterized by repetitive, low-variability tasks where human intervention might introduce unnecessary complexities or biases, thus reducing effectiveness.

ğŸ”¹ FINAL CRITIQUE:

The insight introduces a conceptual ambiguity by emphasizing human oversight without defining clear boundaries for what constitutes "balanced decision-making," thereby creating a tension between efficiency gains through automation and the assumed protective value of human judgment.

---

**INSIGHT MODULE 4:**

ORIGINAL INSIGHT:

"Ethical challengesâ€”including data bias and privacy concernsâ€”in AI-driven drug discovery represent strategic risks that, if unaddressed, can compromise both operational outcomes and corporate reputation." **[Empirical]**

ğŸ”¹ COUNTERFACTUAL SCENARIO:

In an emerging-market pharmaceutical firm operating under relaxed data privacy regulations and social acceptance of aggressive data mining, ignoring ethical concerns significantly enhances operational speed and market dominance, positively affecting outcomes and bolstering corporate reputation within its local market context.

ğŸ”¹ ASSUMPTIONS & BIASES:

- Overconfidence in universality: Assumes ethical considerations and reputational risks uniformly influence all markets or contexts, ignoring geographic and cultural variability in ethical standards.
- Simplistic causality: Links ethical challenges directly to operational outcomes and reputation without nuance or recognition of contexts where unethical behavior may temporarily yield positive results.

ğŸ”¹ CONTEXT LIMITATIONS:

The insight breaks down in geographical or regulatory contexts where ethical oversight is weak, consumer expectations differ substantially, or competition incentivizes rapid growth at the expense of rigorous ethical compliance.

ğŸ”¹ FINAL CRITIQUE:

The insight oversimplifies the relationship between ethics, operational success, and reputation, creating conceptual tension by neglecting market diversity and trade-offs between short-term operational efficiency and long-term ethical integrity.

## You (2025-03-23T19:36:26.240000+00:00)

**Objective**:

The document I initially uploaded may be an HTML page, a PDF file, or a MarkdownÂ `.md`Â file. Your task is toÂ **infer the source type**Â of the document (e.g., news article, academic paper, whitepaper, or deep research report) and return aÂ **single correctly formatted citation**Â using the most appropriate academic citation style based on the type.

---

### ğŸ” INSTRUCTIONS FOR You:

### ğŸ§  Step-by-Step Chain of Thought:

1. **Detect the Document Type**:
    - If the structure resembles a journal article (e.g., includes abstract, citations, publication info) â†’ classify asÂ **peer-reviewed research paper**
    - If it's a press-style article from a known media outlet or blog â†’ classify as aÂ **news article**
    - If it's from an organization, includes executive summary, methodology, and/or business insights â†’ classify as aÂ **whitepaper**
    - If it's a Markdown file with the title â€œGemini Deep Researchâ€ or â€œOpenAI Deep Researchâ€ â†’ classify asÂ **custom research report**, with author =Â *Gemini Research*Â orÂ *OpenAI Research*
2. **Extract Key Metadata**:
    - Author(s) (or org)
    - Publication year (or â€œn.d.â€ if missing)
    - Title of the work
    - Source (e.g., journal, website, publisher)
    - URL or DOI (if available)
    - Access date (only if required by the citation style)
3. **Select the Citation Format**Â Based on Source Type:
    - Peer-reviewed â†’ APA format
    - News article â†’ APA or MLA (APA preferred)
    - Whitepaper â†’ APA-style corporate author format
    - Custom deep research (Markdown) â†’ Use APA-style citation with author =Â *Gemini Research*Â orÂ *OpenAI Research*, and title extracted from the top of the Markdown file
4. **Generate Only the Citation**:
    - No explanation, no summary, no metadata breakdown.
    - Return only the final citation string.

---

### ğŸ§¾ Examples to Follow:

- **News Article / Blogpost (APA)**:

    > Lee, M. (2023, December 10). AI regulation debates heat up.Â The Verge.Â https://www.theverge.com/article/ai-regulation-2023
    >
- **Whitepaper (APA)**:

    > IBM. (2022).Â AI and business transformation: Strategy guide.Â https://www.ibm.com/ai-business-strategy.pdf
    >
- **Research Paper (APA)**:

    > Nguyen, L. T., & Zhao, Q. (2021). Neural-symbolic reasoning for robotics.Â Journal of Artificial Intelligence Research,Â 68(3), 123â€“145.Â https://doi.org/10.1613/jair.1.13254
    >
- **Gemini Deep Research (APA-style whitepaper)**:

    > Gemini Research. (2024).Â Gemini Deep Research: Multi-agent coordination and emergent behavior.Â https://yourlink.comÂ (or omit if no URL)
    >

---

### ğŸ§· Constraints:

- DoÂ **not**Â explain what youâ€™re doing.
- Output must be aÂ **single-line formatted citation only**.
- If metadata is incomplete, use APA-style fallbacks (e.g., "n.d." for no date, "Author" if missing).

## ChatGPT (2025-03-23T19:36:27.445163+00:00)

Blanco-GonzÃ¡lez, A., CabezÃ³n, A., Seco-GonzÃ¡lez, A., Conde-Torres, D., Antelo-Riveiro, P., PiÃ±eiro, Ã., & Garcia-Fandino, R. (2023). The role of AI in drug discovery: Challenges, opportunities, and strategies. *Pharmaceuticals, 16*(6), 891. https://doi.org/10.3390/ph16060891
